Estudio y comparación de una instalación fotovoltaica de autoconsumo con y sin acumulación para una granja porcina

Este Trabajo de Fin de Grado está basado en el estudio de la instalación de paneles fotovoltaicos para el autoconsumo de una industria con y sin uso de acumuladores. Para ello, se ha utilizado el software PVsyst 6.8.8 diseñado para cálculo de sistemas fotovoltaicos y la información otorgada por la empresa PROYECTARENOVABLES CONTROL SLU, donde realicé las prácticas. Se estudiará una industria en particular usando distintas potencias pico y se analizarán los resultados. Posteriormente, se realizará el mismo proceso utilizando acumuladores. Por último, se hará una comparación cualitativa y cuantitativa entre la producción generada neta entre PVsyst 6.8.8 y SIZE Pro -herramienta propia de cálculo de PROYECTARENOVABLES CONTROL SLU-.This Final Degree Project is based on the study of the installation of photovoltaic panels for self-consumption in an industry with and without the use of accumulators. I have used PVsyst 6.8.8 software, designed for the calculation of photovoltaic systems and the information provided by the company PROYECTARENOVABLES CONTROL SLU where I have been working. A particular industry will be studied using different maximum (peak) powers and the results will be analyzed. Subsequently, the same process will be carried out using accumulators. Ultimately, a qualitative and quantitative comparison will be made between the net generated production between PVsyst 6.8.8 and SIZE Pro -PROYECTARENOVABLES CONTROL SLU's own calculation tool-.Departamento de Ingeniería EléctricaGrado en Ingeniería en Tecnologías Industriale

Digitalización de un curso para la utilización de softwares de investigación y su aplicación en el desarrollo de Trabajos Fin de Grado (TFGs) o Trabajos Fin de Máster (TFMs)

Memoria ID-0092. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2017-2018

Enseñanza virtual de softwares de investigación cualitativa para su aplicación en investigaciones que requieran aplicación de metodología en diferentes asignaturas

Memoria ID-093. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2018-2019

Tailoring the thermoelectric properties of Skutterudites by nanocomposites

Póster presentado en la 34th Annual International Conference on Thermoelectrics (ICT) y en la 13th European Conference on Thermoelectrics(ECT), celebradas en Dresden del 28 de junio al 2 de julio de 2015.Skutterudites have attracted great attention for their promising potential on thermoelectric applications, such as harvesting the heat generated in industrial processes and automotive operations. To improve their thermoelectric figure of merit ,emphasis has gone into modifying the band structure through doping to enhance the Power Factor and reducing thermal conductivity through increasing phonon scattering by filling and in-situ nanocomposites formation.Depending on the nature of the nanoinclusions and the proportion in the matrix, it is possible to tailor the thermoelectric properties. In this work, different concentrations of oxides were included in a one-step synthesis mechanism, obtaining the Skutterudite phase with nanoinclusions and therefore, achieving lower thermal conductivities than those reported in literature.Peer Reviewe

Cualificación en los Objetivos establecidos en la Agenda 2030 de estudiantes y profesores en el Máster Universitario en Profesor de Educación Secundaria Obligatoria y Bachillerato, Formación Profesional y Enseñanza de Idiomas (MUPES)

Memoria ID2022-157 Ayudas de la Universidad de Salamanca para la innovación docente, curso 2022-2023

Effectiveness of an intervention for improving drug prescription in primary care patients with multimorbidity and polypharmacy:Study protocol of a cluster randomized clinical trial (Multi-PAP project)

This study was funded by the Fondo de Investigaciones Sanitarias ISCIII (Grant Numbers PI15/00276, PI15/00572, PI15/00996), REDISSEC (Project Numbers RD12/0001/0012, RD16/0001/0005), and the European Regional Development Fund ("A way to build Europe").Background: Multimorbidity is associated with negative effects both on people's health and on healthcare systems. A key problem linked to multimorbidity is polypharmacy, which in turn is associated with increased risk of partly preventable adverse effects, including mortality. The Ariadne principles describe a model of care based on a thorough assessment of diseases, treatments (and potential interactions), clinical status, context and preferences of patients with multimorbidity, with the aim of prioritizing and sharing realistic treatment goals that guide an individualized management. The aim of this study is to evaluate the effectiveness of a complex intervention that implements the Ariadne principles in a population of young-old patients with multimorbidity and polypharmacy. The intervention seeks to improve the appropriateness of prescribing in primary care (PC), as measured by the medication appropriateness index (MAI) score at 6 and 12months, as compared with usual care. Methods/Design: Design:pragmatic cluster randomized clinical trial. Unit of randomization: family physician (FP). Unit of analysis: patient. Scope: PC health centres in three autonomous communities: Aragon, Madrid, and Andalusia (Spain). Population: patients aged 65-74years with multimorbidity (≥3 chronic diseases) and polypharmacy (≥5 drugs prescribed in ≥3months). Sample size: n=400 (200 per study arm). Intervention: complex intervention based on the implementation of the Ariadne principles with two components: (1) FP training and (2) FP-patient interview. Outcomes: MAI score, health services use, quality of life (Euroqol 5D-5L), pharmacotherapy and adherence to treatment (Morisky-Green, Haynes-Sackett), and clinical and socio-demographic variables. Statistical analysis: primary outcome is the difference in MAI score between T0 and T1 and corresponding 95% confidence interval. Adjustment for confounding factors will be performed by multilevel analysis. All analyses will be carried out in accordance with the intention-to-treat principle. Discussion: It is essential to provide evidence concerning interventions on PC patients with polypharmacy and multimorbidity, conducted in the context of routine clinical practice, and involving young-old patients with significant potential for preventing negative health outcomes. Trial registration: Clinicaltrials.gov, NCT02866799Publisher PDFPeer reviewe

A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care

15 p.-3 fig.-3 tab.Introduction:The clinical effect of domperidone against COVID-19 has been investigated in a double-blind phase III clinical trial (EudraCT number 2021-001228-17). Domperidone has shown in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential immudolatory properties through the stimulation of prolactin secretion.Patients and methods:The efficacy of oral domperidone plus standard of care (SOC; n = 87) versus placebo plus SOC (n = 86) was evaluated in a 28-day randomized double-blind multicentre study in primary health care centres. A total of 173 outpatients with mild-to-moderate COVID-19 were included. Three daily doses of 10 mg (30 mg/day) of domperidone or placebo were administered for 7 days. Reduction of viral load on day 4 was the primary efficay endpoint. It was estimated in saliva samples by reverse transcription-quantitative polymerase chain reaction (RT-qPCR), as the cycle thresholds detected ORF1ab, N Protein and S Protein genes.Results:A significant reduction in the viral load was observed (p < 0.001) from baseline to days 4, 7 and 14 of the three genes studied with non-significant differences between domperidone and placebo groups. Twenty-three patients (13.3%) experienced adverse events, 14 patients in the domperidone group (16.1%) and 9 patients in the placebo group (10.5%). No patients needed to be hospitalized.Conclusion: Results do not prove the use of domperidone as antiviral in patients with COVID-19.This research was funded by CSIC (grant no. PIE 201980E024) and by the European Commission: NextGeneration EU (Regulation EU 2020/2094) through CSIC’s Global Health Platform (PTI Salud Global). The study sponsor was Agencia Estatal Consejo Superior de Investigaciones Científicas, M.P. (CSIC), Madrid, Spain. The sponsor was involved in the design, data interpretation, manuscript review and the decision to submit the article for publication.Peer reviewe

Role of age and comorbidities in mortality of patients with infective endocarditis

[Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. [Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. [Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. [Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group